The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy

Arthritis and Rheumatism

Volumn 60, Issue 1, 2009, Pages 290-298

  Jansen, Nathalie W D ^a   Roosendaal, Goris ^a   Lundin, Björn ^b   Heijnen, Lily ^a,c   Mauser Bunschoten, Evelien ^a   Bijlsma, Johannes W J ^a   Theobald, Matthias ^a   Lafeber, Floris P J G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Rehabilitation Centre De Trappenberg   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C TERMINAL COLLAGEN TYPE 2 TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CHONDROINTIN SULFATE 846; CHONDROITIN SULFATE; COLLAGEN TYPE 2; UNCLASSIFIED DRUG;

ADULT; ANKLE RADIOGRAPHY; ARTHRITIS; ARTHROPATHY; ARTICLE; ASSAY; BLOOD LEVEL; CLINICAL ARTICLE; DISEASE SEVERITY; ELBOW RADIOGRAPHY; HEMOPHILIA; HUMAN; KNEE RADIOGRAPHY; OSTEOARTHRITIS; OSTEOPOROSIS; PETTERSSON SCORE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; URINE LEVEL;

ADULT; BIOLOGICAL MARKERS; CARTILAGE; CHONDROITIN SULFATES; COLLAGEN TYPE II; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; JOINT DISEASES; JOINTS; REGRESSION ANALYSIS;

EID: 58249104986     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24184     Document Type: Article

References (42)

1. Sumer EU, Schaller S, Sondergaard BC, Tanko LB, Qvist P. Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review. Biomarkers 2006;11:485-506.
2. Henrotin Y, Addison S, Kraus V, Deberg M. Type II collagen markers in osteoarthritis: what do they indicate? Curr Opin Rheumatol 2007;19:444-50.
3. Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-15.
4. Mouritzen U, Christgau S, Lehmann HJ, Tanko LB, Christiansen C. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 2003;62:332-6.
5. Garnero P, Landewe R, Boers M, Verhoeven A, van der Linden S, Christgau S, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002;46:2847-56.
6. Jung M, Christgau S, Lukoschek M, Henriksen D, Richter W. Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis. Pathobiology 2004;71:70-6.
7. Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004;50:2471-8.
8. Landewe R, Geusens P, Boers M, van der Heijde D, Lems W, TeKoppele J, et al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004;50:1390-9.
9. Hedbom E, Antonsson P, Hjerpe A, Aeschlimann D, Paulsson M, Rosa-Pimentel E, et al. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992;267:6132-6.
10. Halasz K, Kassner A, Morgelin M, Heinegard D. COMP acts as a catalyst in collagen fibrillogenesis. J Biol Chem 2007;282:31166-73.
11. Recklies AD, Baillargeon L, White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum 1998;41:997-1006.
12. Muller G, Michel A, Altenburg E. COMP (cartilage oligomeric matrix protein) is synthesized in ligament, tendon, meniscus, and articular cartilage. Connect Tissue Res 1998;39:233-44.
13. Neidhart M, Hauser N, Paulsson M, DiCesare PE, Michel BA, Hauselmann HJ. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 1997;36:1151-60.
14. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999;42:2356-64.
15. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007;56:3236-47.
16. Vilim V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K. Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 2002;10:707-13.
17. Sharif M, Kirwan JR, Elson CJ, Granell R, Clarke S. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum 2004;50:2479-88.
18. Forslind K, Eberhardt K, Jonsson A, Saxne T. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol 1992;31:593-8.
19. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-5.
20. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
21. Downs JT, Lane CL, Nestor NB, McLellan TJ, Kelly MA, Karam GA, et al. Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. J Immunol Methods 2001;247:25-34.
22. Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods 2004;294:145-53.
23. Rizkalla G, Reiner A, Bogoch E, Poole AR. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 1992;90:2268-77.
24. Lohmander LS, Ionescu M, Jugessur H, Poole AR. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum 1999;42:534-44.
25. Mansson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR, et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995;95:1071-7.
26. Raffini L, Manno C. Modern management of haemophilic arthropathy. Br J Haematol 2007;136:777-87.
27. Roosendaal G, van Rinsum AC, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease. Histopathology 1999;34:144-53.
28. Rodriguez-Merchan EC. The destructive capabilities of the synovium in the haemophilic joint. Haemophilia 1998;4:506-10.
29. Roosendaal G, Mauser-Bunschoten EP, de Kleijn P, Heijnen L, van den Berg HM, van Rinsum AC, et al. Synovium in haemophilic arthropathy. Haemophilia 1998;4:502-5.
30. Roosendaal G, Vianen ME, Wenting MJ, van Rinsum AC, van den Berg HM, Lafeber FP, et al. Iron deposits and catabolic properties of synovial tissue from patients with haemophilia. J Bone Joint Surg Br 1998;80:540-5.
31. Roosendaal G, Lafeber FP. Blood-induced joint damage in hemophilia. Semin Thromb Hemost 2003;29:37-42.
32. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006;12 Suppl 3:117-21.
33. Buckwalter JA, Mankin HJ. Articular cartilage: tissue design and chondrocyte-matrix interactions. Instr Course Lect 1998;47:477-86.
34. Garnero P. Noninvasive biochemical markers in osteoarthritis. In: Moskowitz RW, Altman RD, Hochberg MC, Buckwalter JA, Goldberg VM, editors. Osteoarthritis. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 215-32.
35. Pettersson H GM. Diagnostic imaging in hemophilia: musculoskeletal and other hemorrhagic complications.. Berlin: Springer-Verlag; 1985. p. 28-54.
36. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980;149:153-9.
37. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, et al. Serum CrossLaps one step ELISA: first application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998;44:2281-9.
38. Andersson ML, Petersson IF, Karlsson KE, Jonsson EN, Mansson B, Heinegard D, et al. Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis. Ann Rheum Dis 2006;65:1490-4.
39. Kong SY, Stabler TV, Criscione LG, Elliott AL, Jordan JM, Kraus VB. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 2006;54:2496-504.
40. Fischer K, van Hout BA, van der Bom JG, Grobbee DE, van den Berg HM. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol 2002;43:528-32.
41. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977;59:287-305.
42. Roosendaal G, TeKoppele JM, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Blood-induced joint damage: a canine in vivo study. Arthritis Rheum 1999;42:1033-9.